GeneDx (WGS) Competitors $69.48 +1.22 (+1.79%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends WGS vs. HIMS, RDNT, OPCH, GH, SHC, VCYT, BTSG, LFST, SGRY, and CONShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), RadNet (RDNT), Option Care Health (OPCH), Guardant Health (GH), Sotera Health (SHC), Veracyte (VCYT), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Surgery Partners (SGRY), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry. GeneDx vs. Hims & Hers Health RadNet Option Care Health Guardant Health Sotera Health Veracyte BrightSpring Health Services LifeStance Health Group Surgery Partners Concentra Group Holdings Parent Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in HIMS or WGS? 63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by insiders. Comparatively, 27.3% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer HIMS or WGS? In the previous week, Hims & Hers Health had 13 more articles in the media than GeneDx. MarketBeat recorded 24 mentions for Hims & Hers Health and 11 mentions for GeneDx. Hims & Hers Health's average media sentiment score of 0.64 beat GeneDx's score of 0.41 indicating that Hims & Hers Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 14 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in HIMS or WGS? Hims & Hers Health received 30 more outperform votes than GeneDx when rated by MarketBeat users. However, 50.00% of users gave GeneDx an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformHims & Hers HealthOutperform Votes4139.05% Underperform Votes6460.95% GeneDxOutperform Votes1150.00% Underperform Votes1150.00% Which has preferable valuation and earnings, HIMS or WGS? Hims & Hers Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$872M6.97-$23.55M$0.4463.19GeneDx$202.57M9.42-$175.77M-$3.11-22.34 Do analysts rate HIMS or WGS? Hims & Hers Health presently has a consensus target price of $25.13, indicating a potential downside of 9.60%. GeneDx has a consensus target price of $70.67, indicating a potential upside of 1.71%. Given GeneDx's stronger consensus rating and higher possible upside, analysts clearly believe GeneDx is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35GeneDx 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is HIMS or WGS more profitable? Hims & Hers Health has a net margin of 8.19% compared to GeneDx's net margin of -31.25%. Hims & Hers Health's return on equity of 10.97% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health8.19% 10.97% 8.29% GeneDx -31.25%-13.35%-6.91% Which has more volatility and risk, HIMS or WGS? Hims & Hers Health has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. SummaryHims & Hers Health beats GeneDx on 12 of the 18 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.91B$625.40M$5.21B$9.15BDividend YieldN/A2.02%5.13%4.03%P/E Ratio-22.3433.5688.4817.36Price / Sales9.424.171,243.3177.98Price / CashN/A23.8143.7535.97Price / Book7.912.845.314.79Net Income-$175.77M-$3.80M$122.62M$225.00M7 Day Performance-18.27%-3.19%0.61%2.62%1 Month Performance-10.23%1.43%2.55%3.81%1 Year Performance2,044.44%177.38%25.31%20.10% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx1.5839 of 5 stars$69.48+1.8%$70.67+1.7%+2,044.4%$1.91B$202.57M-22.341,200Gap UpHIMSHims & Hers Health3.5508 of 5 stars$25.73+1.3%$25.13-2.3%+234.2%$5.62B$1.24B58.481,046Short Interest ↑RDNTRadNet4.2693 of 5 stars$66.07-3.9%$84.75+28.3%+58.4%$4.89B$1.77B-943.728,970OPCHOption Care Health4.7478 of 5 stars$27.57+14.9%$29.71+7.8%-9.0%$4.69B$4.78B23.175,600Positive NewsGHGuardant Health3.8987 of 5 stars$37.79+2.9%$40.60+7.4%+57.9%$4.67B$692.26M-8.911,779Short Interest ↓SHCSotera Health3.2821 of 5 stars$13.01-0.8%$16.08+23.6%-13.4%$3.68B$1.12B52.043,000VCYTVeracyte3.9709 of 5 stars$42.51+2.3%$41.13-3.3%+59.0%$3.29B$425.33M-283.40790Analyst UpgradeBTSGBrightSpring Health Services1.4523 of 5 stars$17.23+0.3%$18.65+8.3%N/A$3.00B$10.59B-66.2735,000News CoverageLFSTLifeStance Health Group1.2251 of 5 stars$7.64-1.2%$8.70+13.9%+17.2%$2.92B$1.21B-29.389,325Short Interest ↓Positive NewsSGRYSurgery Partners2.2775 of 5 stars$20.88+1.1%$36.56+75.1%-37.1%$2.65B$2.99B-43.5012,200CONConcentra Group Holdings ParentN/A$20.51+4.0%$28.50+39.0%N/A$2.61B$1.88B0.0011,000Lockup ExpirationPositive News Related Companies and Tools Related Companies HIMS Competitors RDNT Competitors OPCH Competitors GH Competitors SHC Competitors VCYT Competitors BTSG Competitors LFST Competitors SGRY Competitors CON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:WGS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WGS Stock Alerts